Keros Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	2,156	1,191	1,323	1,369	1,424	-	-
Market Cap Growth	-	-9.94%	-3.39%	-3.86%	-	-	-
Enterprise Value	1,737	873	1,056	1,139	1,159	-6	-23
PE Ratio	-7.79	-7.79	-12.63	-23.30	-31.39	-	-
PS Ratio	13606.67	7888.64	-	68.11	-	-	-
PB Ratio	6.18	3.59	4.77	5.63	5.44	-	-
P/FCF Ratio	-9.38	-9.38	-18.55	-21.67	-38.29	-	-
P/OCF Ratio	-9.57	-9.57	-18.88	-22.03	-38.60	-	-
EV/Sales Ratio	11501.27	5783.24	-	56.66	-	-0.59	-2.26
EV/EBITDA Ratio	-5.80	-5.80	-10.24	-20.40	-25.80	0.43	12.62
EV/EBIT Ratio	-5.71	-5.71	-10.08	-20.07	-25.46	0.41	10.79
EV/FCF Ratio	-6.88	-6.88	-14.80	-18.03	-31.17	0.36	-3.31
Debt / Equity Ratio	0.04	0.04	0.05	0.00	0.00	-0.07	-0.11
Debt / EBITDA Ratio	-0.10	-0.10	-0.13	-0.02	-0.02	-0.09	-0.44
Debt / FCF Ratio	-0.11	-0.11	-0.19	-0.02	-0.02	-0.08	0.12
Quick Ratio	13.64	13.64	16.94	21.05	37.03	1.80	2.07
Current Ratio	14.25	14.25	17.27	21.23	37.27	1.99	2.23
Asset Turnover	0	0	0	0.08	0	0.52	-
Interest Coverage	-	-	-104678.00	-14182.25	-7587.83	-1766.00	-
Return on Equity (ROE)	-46.70%	-46.70%	-43.90%	-24.80%	-35.60%	106.20%	-
Return on Assets (ROA)	-42.60%	-42.60%	-41.00%	-23.80%	-29.30%	-73.70%	-
Return on Capital (ROIC)	-49.02%	-49.02%	-39.49%	-23.08%	-17.77%	58.13%	26.44%
Earnings Yield	-7.45%	-12.84%	-7.91%	-4.29%	-3.19%	-	-
FCF Yield	-6.18%	-10.66%	-5.39%	-4.61%	-2.61%	-	-
Buyback Yield / Dilution	-16.66%	-16.66%	-8.17%	-50.48%	-566.41%	-7.01%	-
Total Shareholder Return	-16.66%	-16.66%	-8.17%	-50.48%	-566.41%	-7.01%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).